Medicenna Announces Preliminary Clinical Data Showing Preferential Stimulation of Anti-Cancer Immune Cells with MDNA11 Treatment in the Phase 1/2 ABILITY Study
Stock Information for Medicenna Therapeutics Corp.
Loading
Please wait while we load your information from QuoteMedia.